The earnings season for the drug/biotech sector is now in its final lap, with some large biotech and generic drug companies due to report their third-quarter 2024 results this week.The remaining large drugmakers have already reported their results. Many of these companies beat estimates for both earnings and sales. While some like Pfizer and AbbVie raised their guidance ranges, others like Eli Lilly & Merck cut their outlook.Per the Zacks classification, the pharma/biotech industry comes under the broader M ...